Medivir AB (Medivir AB) Institutional Ownership : 17.70% (As of May. 01, 2024)

View and export this data going back to . Start your Free Trial

What is Medivir AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medivir AB's institutional ownership is 17.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medivir AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medivir AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Medivir AB Institutional Ownership Historical Data

The historical data trend for Medivir AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Institutional Ownership Chart

Medivir AB Historical Data

The historical data trend for Medivir AB can be seen below:

	2022-08-31	2022-09-30	2022-10-31	2022-11-30	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31
Institutional Ownership	17.66	17.38	17.38	17.41	17.57	17.69	17.70	17.70	17.70	17.70

Medivir AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.